+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review

Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It carries out the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, cancer, and human immunodeficiency virus (HIV) infection. Gilead markets its products through commercial teams, third-party distributors and corporate partners. Gilead's commercial teams promote its products through direct field contact with physicians, hospitals, clinics and other healthcare providers. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East, and Africa. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences Inc Key Recent Developments

  • Nov 06, 2024: Gilead Sciences Reports Q3 2024 Results
  • Oct 22, 2024: Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
  • Oct 09, 2024: Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
  • Oct 09, 2024: Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Gilead Sciences Inc - Key Facts
  • Gilead Sciences Inc - Key Employees
  • Gilead Sciences Inc - Key Employee Biographies
  • Gilead Sciences Inc - Major Products and Services
  • Gilead Sciences Inc - History
  • Gilead Sciences Inc - Company Statement
  • Gilead Sciences Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Gilead Sciences Inc - Business Description
  • Product Category: HIV
  • Overview
  • Performance
  • Product Category: Liver Disease
  • Overview
  • Performance
  • Product Category: Oncology
  • Overview
  • Performance
  • Product Category: Other Products
  • Overview
  • Performance
  • Product Category: Veklury
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Other International
  • Performance
  • Geographical Segment: U.S.
  • Performance
  • R&D Overview
  • Gilead Sciences Inc - Corporate Strategy
  • Gilead Sciences Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Gilead Sciences Inc - Strengths
  • Gilead Sciences Inc - Weaknesses
  • Gilead Sciences Inc - Opportunities
  • Gilead Sciences Inc - Threats
  • Gilead Sciences Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Gilead Sciences Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 06, 2024: Gilead Sciences Reports Q3 2024 Results
  • Oct 22, 2024: Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
  • Oct 09, 2024: Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
  • Oct 09, 2024: Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
  • Aug 08, 2024: Gilead Sciences Announces Second Quarter 2024 Financial Results
  • Jul 25, 2024: MoU signing between HCSA Community Services and Tzu-Chi Foundation (Singapore) to support Hepatitis C elimination initiative for former drug abusers in Singapore
  • Jul 25, 2024: Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
  • Jul 25, 2024: Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
  • Jul 22, 2024: Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
  • Jul 18, 2024: Research Identifies Blind Spots That Affect Quality of Life Among People with HIV in Singapore
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Gilead Sciences Inc, Key Facts
  • Gilead Sciences Inc, Key Employees
  • Gilead Sciences Inc, Key Employee Biographies
  • Gilead Sciences Inc, Major Products and Services
  • Gilead Sciences Inc, History
  • Gilead Sciences Inc, Other Locations
  • Gilead Sciences Inc, Subsidiaries
  • Gilead Sciences Inc, Joint Venture
  • Gilead Sciences Inc, Key Competitors
  • Gilead Sciences Inc, Ratios based on current share price
  • Gilead Sciences Inc, Annual Ratios
  • Gilead Sciences Inc, Interim Ratios
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Gilead Sciences Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Gilead Sciences Inc, Performance Chart (2019 - 2023)
  • Gilead Sciences Inc, Ratio Charts
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Precigen Inc
  • Pfizer Inc
  • Incyte Corp
  • GSK plc
  • Earth Science Tech Inc
  • Vividion Therapeutics Inc
  • Ocera Therapeutics Inc
  • Bristol-Myers Squibb India
  • Abbott Laboratories
  • Janssen Therapeutics
  • Intercept Pharmaceuticals Inc
  • United Therapeutics Corp
  • Celgene Corp
  • Kineta Inc
  • Novartis AG
  • Enzon Pharmaceuticals Inc
  • Viracta Therapeutics Inc
  • Merck & Co Inc
  • hVIVO Services Ltd